E
Eiichiro Tominaga
Researcher at Keio University
Publications - 69
Citations - 1453
Eiichiro Tominaga is an academic researcher from Keio University. The author has contributed to research in topics: Cancer & Endometrial cancer. The author has an hindex of 21, co-authored 67 publications receiving 1186 citations.
Papers
More filters
Journal ArticleDOI
ARID1A gene mutation in ovarian and endometrial cancers (Review)
Takashi Takeda,Kouji Banno,Ryuichiro Okawa,Megumi Yanokura,Moito Iijima,Haruko Kunitomi,Kanako Nakamura,Miho Iida,Masataka Adachi,Kiyoko Umene,Yuya Nogami,Kenta Masuda,Yusuke Kobayashi,Eiichiro Tominaga,Daisuke Aoki +14 more
TL;DR: Development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis-associated ovarian cancers and endometrial cancers.
Journal ArticleDOI
MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment
Kouji Banno,Miho Iida,Megumi Yanokura,Iori Kisu,Takashi Iwata,Eiichiro Tominaga,Kyoko Tanaka,Daisuke Aoki +7 more
TL;DR: Methods for diagnosis of cervical cancer include analysis of changes in the levels of specific miRNAs in serum and determination of aberrant hypermethylation of miRN as well as an anti-miR-21 inhibitor developed.
Journal ArticleDOI
Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation.
Shinichi Komiyama,Daisuke Aoki,Eiichiro Tominaga,Nobuyuki Susumu,Yasuhiro Udagawa,Shiro Nozawa +5 more
TL;DR: Patients having ovarian clear cell carcinoma with pelvic endometRIosis exhibited a better prognosis than those without endometriosis, especially those patients with stage I cancer.
Journal ArticleDOI
Features of ovarian cancer in Lynch syndrome (Review).
Kanako Nakamura,Kouji Banno,Megumi Yanokura,Miho Iida,Masataka Adachi,Kenta Masuda,Arisa Ueki,Yusuke Kobayashi,Hiroyuki Nomura,Akira Hirasawa,Eiichiro Tominaga,Daisuke Aoki +11 more
TL;DR: Molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer, and inhibitors of the phosphatidylinositol 3-kinase/mammalian target of the rapamycin pathway and anti-epidermal growth factor antibodies may have efficacy.
Journal ArticleDOI
Application of microRNA in diagnosis and treatment of ovarian cancer.
Kouji Banno,Megumi Yanokura,Miho Iida,Masataka Adachi,Kanako Nakamura,Yuya Nogami,Kiyoko Umene,Kenta Masuda,Iori Kisu,Hiroyuki Nomura,Fumio Kataoka,Eiichiro Tominaga,Daisuke Aoki +12 more
TL;DR: MicroRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy and Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.